Stock AnalizNatera, Inc. NTRA
Medical Specialities · IPO 2015 · data as of November 13, 2026
Natera, Inc. (NTRA) is a healthcare company listed in the US with a market value of about $46.3B. In the twelve months to September 30, 2026 it had revenue of $2.9B and net income of -$165M, a net margin of -5.7%.
Its overall Stock Analiz score is 1.6 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 881.9, 5-year revenue growth of 43% a year, a 5-year average ROIC of -27%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 94% below the current price.
Score: 1.6 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.9B | $2.3B | $1.7B | $1.1B | $820M | $625M | $391M | $302M | $258M | $211M | $217M |
| Net income | -$165M | -$208M | -$190M | -$435M | -$548M | -$472M | -$230M | -$125M | -$128M | -$138M | -$100M |
| Free cash flow | $52M | $109M | $69M | -$286M | -$479M | -$376M | -$202M | -$68M | -$74M | -$108M | -$97M |
| EPS (diluted) | $-1.13 | $-1.52 | $-1.53 | $-3.78 | $-5.57 | $-5.21 | $-2.84 | $-1.79 | $-2.22 | $-2.59 | $-1.95 |
| Net margin | -5.7% | -9.0% | -11.2% | -40.2% | -66.8% | -75.4% | -58.8% | -41.3% | -49.7% | -65.2% | -46.2% |
| ROIC | — | -12.5% | -12.7% | -31.3% | -39.9% | -37.0% | -30.2% | -25.5% | -110.0% | -141.6% | -41.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 21 analysts is $410.02, 28% above the current price; targets range from $280.00 to $500.00; the consensus rating is “Strong buy”; expected EPS is $-1.53 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Natera stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 94% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Natera pay a dividend?
Not currently.
Is Natera a good stock to buy?
We do not give buy or sell advice. Natera scores 1.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.